Since Our Founding in 1946, We Have Invested in Nearly 4,000 Scientists.
In partnership with donors across the nation, we have invested nearly $450 million.
Every breakthrough in cancer research is a culmination of all the discoveries that came before it. Damon Runyon scientists lay the foundation for future advancement, not only through their work but also through their mentorship of the next generation of leaders in cancer research. We are truly honored to support them.
The below timeline provides a sample of significant accomplishments by Damon Runyon scientists.
2021
Nobel PrizeNobel Prize in Physiology or Medicine (shared) “for their discoveries of receptors for temperature and touch.”
David Julius, PhD
(former member of Fellowship Committee and mentor to 4 Fellows)
Ardem Patapoutian, PhD
(Fellow 1996–99 and Scholar 2002–05)
2020
First therapy targeting "undruggable" KRAS approved
Leadership of the clinical trials for the first KRAS inhibitor, Lumakras, FDA approved for treatment of lung cancer in 2021.
Piro Lito, MD, PhD
(Clinical Investigator 2017–22)
2019
Nobel Prize2019 Nobel Prize in Physiology or Medicine (shared) “for [his] discovery of how cells sense and adapt to oxygen availability.”
William G. Kaelin, Jr., MD
(Damon Runyon Board of Directors)
2018
Completion of the Pan-Cancer Atlas
Compilation of data from more than 11,000 tumors, representing 33 different cancer types, which is an essential resource for scientists developing targeted drugs.
Matthew L. Meyerson, MD, PhD
(Fellow 1995-98)
2015
First combination immunotherapy approved for advanced melanoma
Demonstration of effectiveness of Yervoy plus Opdivo for treatment of advanced melanoma, leading to first FDA approval of a combined immunotherapy the same year.
Jedd D. Wolchok, MD, PhD
(Clinical Investigator 2003–08)
2013
Revolutionary gene editing tool
Development of the CRISPR/Cas9 system capable of editing specific genes in living organisms.
Feng Zhang, PhD
(Innovator 2012-14)